Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions

Metastatic Adult Soft Tissue SarcomaRecurrent Adult Soft Tissue Sarcoma

Interventions

BIOLOGICAL

Durvalumab and Tremelimumab

immun checkpoint inhibitor

DRUG

Doxorubicin

Anthracycline

Trial Locations (1)

Medizinische Hochschule Hannover, Hanover